Bethany Samuelson Bannow Welcomed to Department of Hematology and Medical Oncology at the Cancer Institute Cleveland Clinic
Jame Abraham, Chairman and Professor, Department of Hematology and Medical Oncology at Cleveland Clinic, shared on LinkedIn:
”We are thrilled to welcome Dr, Bethany Samuelson Bannow as the Program Leader of Classical Hematology in the Department of Hematology and Medical Oncology at the Cancer Institute Cleveland Clinic
Dr. Samuelson Bannow earned her medical degree from Oregon Health and Science University completed her residency at the University of California, San Francisco, and her fellowship at the University of Washington.
She has served as an Acting Instructor at the University of Washington and later as Assistant Professor and Associate Professor in Hematology and Oncology at OHSU.
A hematologist, scientist, and educator, Dr. Samuelson Bannow is passionate about advancing the care of patients with bleeding and clotting disorders.
She has led and participated in multiple clinical trials focused on hemophilia, von Willebrand disease, and other bleeding disorders, and her research centers on blood clotting regulation and women’s health in hematology.
She is also actively engaged in professional leadership, serving as Associate Editor of ASH Clinical News, Co-Chair of the Thrombosis Subcommittee of the Foundation for Women and Girls
With Blood Disorders, and on committees for the Hemostasis and Thrombosis Research Society and the American Board of Internal Medicine American Society of Hematology.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives